CA180-357 = Decitabine + Dasatinib for Blast Phase CML
Study title
CA180-357 = Decitabine + Dasatinib for Blast Phase CML [USA]
Scientific title
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [USA]
(Clinicaltrials.gov No. NCT01498445)
Type of study
Treatment of advanced disease
In a single country
Current status
The study was terminated due to slow enrollment.
What is the purpose of the study
Patients with accelerated or blast phase CML are treated with a combination of decitabine and dasatinib. They will take dasatinib by mouth once a day and they will receive decitabine by vein for up to 10 days in each 28-day cycle.
Key inclusion criteria
This study includes patients age 18 years of age or older with chronic myelogenous leukemia in accelerated phase (CML-AP) or in blast phase (CML-BP). Patients may be previously treated or previously untreated.
Key exclusion criteria
Where can I find additional information
Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health
Study sponsor
MD Anderson Cancer Center
Scientific lead / contact
Jorge Cortes
Principal investigator
Jorge Cortes
Study centers / principal investigators
United States
MD Anderson Cancer Center
University of Texas
Houston, Texas